Cost-Effectiveness of the Third-Agent Class in Treatment-Naive Human Immunodeficiency Virus-Infected Patients in Portugal

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Aragão, Filipa ^a,b   Vera, José ^c   Vaz Pinto, Inês ^c  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^b Associação SER   (Portugal)

^c HPP Hospital de Cascais   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PORTUGAL; SIMULATION; SURVIVAL TIME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PATIENT COMPLIANCE; PORTUGAL; PROBABILITY; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84866452611     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044774     Document Type: Article

References (59)

1. European Centre for Disease Prevention and Control/WHO Regional Office for Europe (2011) HIV/AIDS surveillance in Europe 2010. Available: http://ecdc.europa.eu/en/publications/Publications/111129_SUR_Annual_HIV_Report.pdf. Accessed 12 October 2011.
2. WHO Regional Office for Europe (2011) European Health For All database. Available: http://data.euro.who.int/hfadb/. Accessed 12 October 2011.
3. Centro de Vigilância Epidemiológica de Doenças Transmissíveis (2011) A situação da infecção VIH e Sida em Portugal a 31 de Dezembro de 2010. Available: http://www.sida.pt/aaaDefault.aspx?f=3&back=1&id=8324. Accessed 12 October 2011.
4. United Nations Programme on HIV/AIDS (2009) AIDS epidemic update. Available: http://data.unaids.org/pub/Report/2009/JC1700_Epi_Update_2009_en.pdf. Accessed 2 February 2010.
5. INFARMED, Autoridade Nacional do Medicamento e Produtos de Saúde, I.P. (2011) Consumo de Medicamentos em Meio Hospitalar Dezembro 2009. Available: http://www.infarmed.pt/portal/page/portal/INFARMED/MONITORIZACAO_DO_MERCADO/OBSERVATORIO/ANALISE_MENSAL_MERCADO/ANALISE_MERCADO_MEDICAMENTOS_CHNM/2009. Accessed 6 May 2010.
6. INFARMED, Autoridade Nacional do Medicamento e Produtos de Saúde, I.P. (2010) Análise do Mercado de Medicamentos no âmbito do Serviço Nacional de Saúde. Available: http://www.infarmed.pt/portal/page/portal/infarmed/monitorizacao_do_mercado/observatorio/analise_mensal_mercado/analise_mercado_medicamentos_chnm/2009/rel_chnm_200912.pdf. Accessed 6 May 2010.
7. Coordenação Nacional para a Infecção VIH/sida (2009) Recomendações Portuguesas para o Tratamento da Infecção VIH/sida. Available: http://www.portaldasaude.pt/NR/rdonlyres/030A05A2-12E7-4710-832D-BCE84E17C93B/0/i006008.pdf. Accessed 12 June 2011.
8. Department of Health and Human Services (2011) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1- infected adults and adolescents. Available: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 12 February 2011.
9. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304(3): 321-333.
10. Gazzard BG, Anderson J, Babiker A, Boffito M, Brook G, et al. (2008) British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 9: 563-608.
11. European AIDS Clinical Society (2009) Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe. Available: http://www.europeanaidsclinicalsociety.org/guidelinespdf/EACS-EuroGuidelines2009FullVersion.pdf. Accessed 12 February 2011.
12. Coordenação Nacional para a Infecção VIH/sida (2009) Recomendações Portuguesas para o Tratamento da Infecção VIH/SIDA. Available: http://www.sida.pt. Accessed 12 February 2011.
13. Lozano F,Pedro PD, Polo JR, Aldeguer JL, Aguirrebengoa K, Pedro PD, et al. (2011) Documento de consenso de Gesida y PNS sobre el tratamiento antirretroviral del adulto (enero 2011). Available: http://www.gesida-seimc.org/pcientifica/dcconsensos.asp. Accessed 12 February 2011.
14. Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, et al. (2001) The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 344: 824-31.
15. Kagay CR, Porco TC, Liechty CA, Charlebois E, Clark R, et al. (2002) A Monte Carlo simulation for modeling outcomes of AIDS treatment regimens. Pharmacoeconomics 20(4): 215-224.
16. Kühne FC, Chancellor J, Mollon P, Myers DE, Louie M, et al. (2010) A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals. HIV Clin Trials 11(2): 80-99.
17. Johnston KM, Levy AR, Lima VD, Hogg RS, Tyndall MW, et al. (2010) Expanding access to HAART: a cost-effective approach for treating and preventing HIV. AIDS 24(12): 1929-35.
18. Kuhne FC, Chancellor J, Mollon P, Weinstein M, Powderly W (2007) Microsimulation or Cohort Modelling? A Comparative Case Study in HIV Infection. iHEA 2007 6th World Congress: Explorations in Health Economics Paper. Available: http://ssrn.com/abstract=994349. Accessed 12 February 2011.
19. Simpson KN, Strassburger A, Jones WJ, Dietz B, Rajagopalan R, (2009) Comparison of Markov model and discrete-event simulation techniques for HIV. Pharmacoeconomics 27(2): 159-65.
20. Barton P, Bryan S, Robinson S, (2004) Modeling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy 9(2): 110-8.
21. Barton P, Jobanputra P, Wilson J, Bryan S, Burls A, (2004) The use of modeling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess 8(11): 1-91.
22. Barth-Jones DC, Adams AL, Koopman JS (2000) Monte Carlo simulation experiments for analysis of HIV vaccine effects and vaccine trial design. WSC '00 Proceedings of the 32nd conference on Winter simulation: 1985-94.
23. Ying H, Lin F, MacArthur RD, Cohn JA, Barth-Jones DC, et al. (2007) A self-learning fuzzy discrete event system for HIV/AIDS treatment regimen selection. IEEE Trans Syst Man Cybern B Cybern 37(4): 966-79.
24. Vieira IT, Harper PR, Shanani AK, Senna V, (2003) Mother-to-child transmission of HIV: a simulation-based approach for the evaluation of intervention strategies. J Oper Res Soc 54: 713-22.
25. Papke LE, Wooldridge JM, (1996) Econometric methods for fractional response variables with an application to 401(k) plan participation rates. Journal of Applied Econometrics 11: 619-32.
26. McDowell A, Cox NJ (2004) How do you fit a model when the dependent variable is a proportion? Available: http://www.stata.com/support/faqs/stat/logit.html. Accessed 20 June 2008.
27. EMEA- European Medicines Agency (2009) Report for Prezista- Scientific Discussion. Available: http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000707/WC500041754.pdf. Accessed 25 May 2008.
28. Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, et al. (2007) Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 369(9568): 1169-78.
29. Elzi L, Marzolini C, Furrer H, Ledergerber B, Cavassini M, et al. (2010) Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 170(1): 57-65.
30. May M, Porter K, Sterne JA, Royston P, Egger M, (2005) Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. J Clin Epidemiol 58(10): 1033-41.
31. Egger M, May M, Chêne G, Phillips AN, Ledergerber B, et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360(9327): 119-29.
32. Instituto Nacional de Estatística (2009) Tábua Completa de Mortalidade para Portugal 2006-2008. Available: http://ue2007.ine.pt/xportal/xmain?xpid=INE&xpgid=ine_destaques&DESTAQUESdest_boui=56512592&DESTAQUESmodo=2. Accessed 12 March 2010.
33. Administração Central do Sistema de Saúde IP (2009) Catálogo de Aprovisionamento Público da Saúde. Available: http://www.catalogo.min-saude.pt/CAPS/publico/default.asp. Accessed 11 January 2009.
34. Portaria n.o- 132/2009 de 30 de Janeiro de 2009, in DR I Série B, n.o- 21, de 30 de Janeiro de 2009, 660-758- Ministério da Saúde.
35. Llibre-Codina JM, Casado-Gómez MA, Sánchez-de la Rosa R, Pérez-Elías MJ, Santos-González J, et al. (2007) Cost of nucleoside analogue reverse transcriptase inhibitorrelated toxicity in HIV-1-infected patients. Enferm Infecc Microbiol Clin 25(2): 98-107.
36. United Nations Economic Commission for Europe (2010) UNECE STATISTICAL DATABASE, Economic Statistics, Price Index, Consumer Price Index 2010. Available: http://w3.unece.org/pxweb/. Accessed 18 May 2010.
37. Silva EA, Pinto CG, Sampaio C, Pereira JA, Drummond M, et al. (1999) Orientações Metodológicas para Estudos de Avaliação Económica de Medicamentos Ministério da Saúde. Lisboa: Infarmed. 104 p.
38. Simpson KN, Luo MP, Chumney E, Sun E, Brun S, et al. (2004) Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials 5(5): 294-304.
39. Beck EJ, Mandalia S, Lo G, Sharott P, Youle M, et al. (2010) Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based HAART Regimens in the UK, 1996-2006. PLoS ONE 6(5): e20200.
40. Walensky RP, Weinstein MC, Yazdanpanah Y, Losina E, Mercincavage LM, et al. (2007) HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. AIDS 21(8): 973-82.
41. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, et al. (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354(3): 251-60.
42. Greenbaum AH, Wilson LE, Keruly JC, Moore RD, Gebo KA, (2008) Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals. AIDS 22(17): 2331-9.
43. Liddy J (2007) Time to Viral Suppression and Subsequent Failure in ART-Naive Subjects Receiving HAART: Results from the HIV-NAT 006 Cohort. Thailand: College of Public Health Sciences of Chulalongkorn University. 107 p.
44. Phillips AN, Ledergerber B, Bogner JR, Lacombe K, Wiercinska-Drapalo A, et al. (2008) Rate of change in CD4 counts in patients with stable HIV viremia. J Int AIDS Soc (Suppl 1): O17.
45. Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, et al. (2004) Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 364(9428): 51-62.
46. Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, et al. (1999) HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 13(6): F35-43.
47. Le Moing V, Chêne G, Carrieri MP, Alioum A, Brun-Vézinet F, et al. (2002) Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 16(1): 21-9.
48. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, et al. (2005) Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 352(6): 570-85.
49. Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, et al. (2009) Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 361(23): 2230-40.
50. The Antiretroviral Therapy Cohort Collaboration, (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372(9635): 293-9.
51. The Antiretroviral Therapy Cohort Collaboration, (2009) Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol 38(6): 1624-33.
52. Aragão F, Vaz Pinto I, Vera J, (2010) Avaliação Económica do Início Precoce de Tratamento Antiretrovírico em Doentes Infectados pelo VIH-1 em Portugal. Arquivos de Medicina 24(5): 209-32.
53. Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, et al. (2008) Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther 13(7): 927-36.
54. Robbins GK, Daniels B, Zheng H, Chueh H, Meigs JB, et al. (2007) Predictors of antiretroviral treatment failure in an urban HIV clinic. J Acquir Immune Defic Syndr 44(1): 30-7.
55. Beck EJ, Mandalia S, Youle M, Brettle R, Fisher M, et al. (2008) Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002). Int J STD AIDS 19(5): 297-304.
56. Krentz HB, Auld MC, Gill MJ, (2003) The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001. CMAJ 169(2): 106-10.
57. Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED, et al. (2006) Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 20(2): 223-31.
58. Braithwaite RS, Justice AC, Chang CC, Fusco JS, Raffanti SR, et al. (2005) Estimating the proportion of patients infected with HIV who will die of comorbid diseases. Am J Med 118(8): 890-8.
59. Reis A (2007) Adesão à terapêutica na Infecção pelo Vírus da Imunodeficiência Humana. Porto: Faculdade de Psicologia e de Ciências da Universidade do Porto. 159 p.